F.X. Ruiz et al. / Chemico-Biological Interactions 191 (2011) 199–205
205
Lys125, present in 1B10 protein, is also found in low-retinoid
activity enzymes, which indicates that this is not the only struc-
tural determinant for high retinaldehyde reductase activity. In fact,
here we have shown that Lys125 (loop A) and Ser304 (loop C),
the latter being unique to 1B10 and chicken 1B12 (also a highly
active retinaldehyde reductase [38]), are major structural determi-
nants for all-trans-retinaldehyde specificity of 1B10, as assessed by
site-directed mutagenesis and molecular dynamics.
[15] E.A. Pailhoux, A. Martinez, G.M. Veyssiere, C.G. Jean, Androgen-dependent pro-
tein from mouse vas deferens. cDNA cloning and protein homology with the
aldo–keto reductase superfamily, J. Biol. Chem. 265 (1990) 19932–19936.
[16] P.J. Donohue, G.F. Alberts, B.S. Hampton, J.A. Winkles, A delayed-early gene
activated by fibroblast growth factor-1 encodes a protein related to aldose
reductase, J. Biol. Chem. 269 (1994) 8604–8609.
[17] C. Graham, C. Szpirer, G. Levan, D. Carper, Characterization of the aldose
reductase-encoding gene family in rat, Gene 107 (1991) 259–267.
[18] D.J. Hyndman, R. Takenoshita, N.L. Vera, S.C. Pang, T.G. Flynn, Cloning, sequenc-
ing, and enzymatic activity of an inducible aldo–keto reductase from Chinese
hamster ovary cells, J. Biol. Chem. 272 (1997) 13286–13291.
[19] O. Gallego, F.X. Ruiz, A. Ardèvol, M. Domínguez, R. Álvarez, A.R. de Lera, C. Rovira,
J. Farrés, I. Fita, X. Parés, Structural basis for the high all-trans-retinaldehyde
reductase activity of the tumor marker AKR1B10, Proc. Natl. Acad. Sci. U.S.A.
104 (2007) 20764–20769.
[20] A. Dereeper, V. Guignon, G. Blanc, S. Audic, S. Buffet, F. Chevenet, J.F. Dufa-
yard, S. Guindon, V. Lefort, M. Lescot, J.M. Claverie, O. Gascuel, Phylogeny.fr:
robust phylogenetic analysis for the non-specialist, Nucleic Acids Res. 36 (2008)
W465–W469.
Conflict of interest
The authors declare that there are no conflicts of interest.
Acknowledgements
[21] J.D. Thompson, D.G. Higgins, T.J. Gibson, CLUSTAL W: improving the sensitiv-
ity of progressive multiple sequence alignment through sequence weighting,
position-specific gap penalties and weight matrix choice, Nucleic Acids Res. 22
(1994) 4673–4680.
[22] M. Spite, S.P. Baba, Y. Ahmed, O.A. Barski, K. Nijhawan, J.M. Petrash, A. Bhat-
nagar, S. Srivastava, Substrate specificity and catalytic efficiency of aldo–keto
reductases with phospholipid aldehydes, Biochem. J. 405 (2007) 95–105.
[23] B. Crosas, D.J. Hyndman, O. Gallego, S. Martras, X. Parés, T.G. Flynn, J. Farrés,
Human aldose reductase and human small intestine aldose reductase are effi-
cient retinal reductases: consequences for retinoid metabolism, Biochem. J. 373
(2003) 973–979.
[24] W.D. Cornell, P. Cieplak, C.I. Bayly, I.R. Gould, K.M. Merz, D.M. Ferguson, D.C.
Spellmeyer, T. Fox, J.W. Caldwell, P.A. Kollman, A second generation force field
for the simulation of proteins, nucleic acids, and organic molecules, J. Am. Chem.
Soc. 118 (1996) 2309–12309, 117 (1995) 5179.
[25] D.A. Pearlman, D.A. Case, J.W. Caldwell, W.S. Ross, T.E. Cheatham, S. Debolt,
D. Ferguson, G. Seibel, P. Kollman, Amber, a package of computer-programs
for applying molecular mechanics, normal-mode analysis, molecular-dynamics
and free-energy calculations to simulate the structural and energetic properties
of molecules, Comput. Phys. Commun. 91 (1995) 1–41.
[26] S. Endo, T. Matsunaga, T. Kuragano, S. Ohno, Y. Kitade, K. Tajima, O. El-
Kabbani, A. Hara, Properties and tissue distribution of a novel aldo–keto
reductase encoding in a rat gene (Akr1b10), Arch. Biochem. Biophys. 503 (2010)
230–237.
[27] S.E. Old, S. Sato, P.F. Kador, D.A. Carper, In vitro expression of rat lens
aldose reductase in Escherichia coli, Proc. Natl. Acad. Sci. U.S.A. 87 (1990)
4942–4945.
[28] S. Srivastava, T.M. Harter, A. Chandra, A. Bhatnagar, S.K. Srivastava, J.M. Petrash,
Kinetic studies of FR-1, a growth factor-inducible aldo–keto reductase, Bio-
chemistry 37 (1998) 12909–12917.
[29] D. Cao, S.T. Fan, S.S. Chung, Identification and characterization of a novel human
aldose reductase-like gene, J. Biol. Chem. 273 (1998) 11429–11435.
[30] E.T. Lau, D. Cao, C. Lin, S.K. Chung, S.S. Chung, Tissue-specific expression of
two aldose reductase-like genes in mice: abundant expression of mouse vas
deferens protein and fibroblast growth factor-regulated protein in the adrenal
gland, Biochem. J. 312 (1995) 609–615.
[31] A.M. Lefrancois-Martinez, C. Tournaire, A. Martinez, M. Berger, S. Daoudal, D.
Tritsch, G. Veyssière, C. Jean, Product of side-chain cleavage of cholesterol,
isocaproaldehyde, is an endogenous specific substrate of mouse vas deferens
protein, an aldose reductase-like protein in adrenocortical cells, J. Biol. Chem.
274 (1999) 32875–32880.
[32] S. Endo, T. Matsunaga, H. Mamiya, A. Hara, Y. Kitade, K. Tajima, O. El-Kabbani,
Characterization of a rat NADPH-dependent aldo–keto reductase (AKR1B13)
induced by oxidative stress, Chem. Biol. Interact. 178 (2009) 151–157.
[33] S. Endo, T. Matsunaga, A. Fujita, K. Tajima, O. El-Kabbani, A. Hara, Rat aldose
reductase-like protein (AKR1B14) efficiently reduces the lipid peroxidation
product 4-oxo-2-nonenal, Biol. Pharm. Bull. 33 (2010) 1886–1890.
[34] S. Endo, T. Matsunaga, M. Soda, K. Tajima, H.T. Zhao, O. El-Kabbani, A. Hara,
Selective inhibition of the tumor marker AKR1B10 by antiinflammatory N-
phenylanthranilic acids and glycyrrhetic acid, Biol. Pharm. Bull. 33 (2010)
886–890.
[35] T. Matsunaga, S. Endo, M. Soda, H.T. Zhao, O. El-Kabbani, K. Tajima, A.
Hara, Potent and selective inhibition of the tumor marker AKR1B10 by bis-
demethoxycurcumin: probing the active site of the enzyme with molecular
modeling and site-directed mutagenesis, Biochem. Biophys. Res. Commun. 389
(2009) 128–132.
[36] M. Verma, H.J. Martin, W. Haq, T.R. O’Connor, E. Maser, G.K. Balendiran, Inhibit-
ing wild-type and C299S mutant AKR1B10; a homologue of aldose reductase
upregulated in cancers, Eur. J. Pharmacol. 584 (2008) 213–221.
[37] H.T. Zhao, M. Soda, S. Endo, A. Hara, O. El-Kabbani, Selectivity determinants of
inhibitor binding to the tumour marker human aldose reductase-like protein
(AKR1B10) discovered from molecular docking and database screening, Eur. J.
Med. Chem. 45 (2010) 4354–4357.
We thank Professor T. Geoffrey Flynn (Department of Bio-
chemistry, Queen’s University, Kingston, Ontario, Canada) for his
support. We wish to acknowledge the assistance of Terry Griest
and Theresa Harter (Department of Ophthalmology, Washing-
ton University) toward the identification and characterization of
novel aldo–keto reductases. We acknowledge the computer sup-
port, technical expertise, and assistance provided by the Barcelona
Supercomputing Center-Centro Nacional de Supercomputación.
This work was supported by grants from Dirección General de
Investigación (BFU2008-02945 and FIS2008-03845), Generalitat de
Catalunya (2009SGR795 and 2009SGR1309) and by NIH grant EY
05856. A.A. thanks the Spanish Ministry of Education for an FPU
predoctoral fellowship.
References
[1] Y. Jin, T.M. Penning, Aldo–keto reductases and bioactivation/detoxication,
Annu. Rev. Pharmacol. Toxicol. 47 (2007) 263–292.
[2] J.M. Jez, M.J. Bennett, B.P. Schlegel, M. Lewis, T.M. Penning, Comparative
anatomy of the aldo–keto reductase superfamily, Biochem. J. 326 (1997)
625–636.
[3] J.M. Jez, T.G. Flynn, T.M. Penning, A new nomenclature for the aldo–keto reduc-
tase superfamily, Biochem. Pharmacol. 54 (1997) 639–647.
[4] C. Yabe-Nishimura, Aldose reductase in glucose toxicity:
a potential tar-
get for the prevention of diabetic complications, Pharmacol. Rev. 50 (1998)
21–33.
[5] O. Gallego, O.V. Belyaeva, S. Porté, F.X. Ruiz, A.V. Stetsenko, E.V. Shabrova,
N.V. Kostereva, J. Farrés, X. Parés, N.Y. Kedishvili, Comparative functional
analysis of human medium-chain dehydrogenases, short-chain dehydroge-
nases/reductases and aldo–keto reductases with retinoids, Biochem. J. 399
(2006) 101–109.
[6] S. Fukumoto, N. Yamauchi, H. Moriguchi, Y. Hippo, A. Watanabe, J. Shibahara, H.
Taniguchi, S. Ishikawa, H. Ito, S. Yamamoto, H. Iwanari, M. Hironaka, Y. Ishikawa,
T. Niki, Y. Sohara, T. Kodama, M. Nishimura, M. Fukayama, H. Dosaka-Akita, H.
Aburatani, Overexpression of the aldo–keto reductase family protein AKR1B10
is highly correlated with smokers’ non-small cell lung carcinomas, Clin. Cancer
Res. 11 (2005) 1776–1785.
[7] T.M. Penning, AKR1B10: a new diagnostic marker of non-small cell lung carci-
noma in smokers, Clin. Cancer Res. 11 (2005) 1687–1690.
[8] A.M. Quinn, R.G. Harvey, T.M. Penning, Oxidation of PAH trans-dihydrodiols
by human aldo–keto reductase AKR1B10, Chem. Res. Toxicol. 21 (2008)
2207–2215.
[9] F.X. Ruiz, O. Gallego, A. Ardèvol, A. Moro, M. Domínguez, S. Álvarez, R. Álvarez,
A.R. de Lera, C. Rovira, I. Fita, X. Parés, J. Farrés, Aldo–keto reductases from the
AKR1B subfamily: retinoid specificity and control of cellular retinoic acid levels,
Chem. Biol. Interact. 178 (2009) 171–177.
[10] R. Satow, M. Shitashige, Y. Kanai, F. Takeshita, H. Ojima, T. Jigami, K. Honda,
T. Kosuge, T. Ochiya, S. Hirohashi, T. Yamada, Combined functional genome
survey of therapeutic targets for hepatocellular carcinoma, Clin. Cancer Res. 16
(2010) 2518–2528.
[11] R. Wang, G. Wang, M.J. Ricard, B. Ferris, Y. Strulovici-Barel, J. Salit, N.R. Hackett,
L.J. Gudas, R.G. Crystal, Smoking-induced up-regulation of AKR1B10 expression
in the airway epithelium of healthy individuals, Chest 138 (2010) 1402–1410.
[12] O.A. Barski, S.M. Tipparaju, A. Bhatnagar, The aldo–keto reductase superfamily
and its role in drug metabolism and detoxification, Drug Metab. Rev. 40 (2008)
553–624.
[13] R.D. Mindnich, T.M. Penning, Aldo–keto reductase (AKR) superfamily:
genomics and annotation, Hum. Genomics 3 (2009) 362–370.
[14] T. Gui, T. Tanimoto, Y. Kokai, C. Nishimura, Presence of a closely related sub-
group in the aldo–ketoreductase family of the mouse, Eur. J. Biochem. 227
(1995) 448–453.
[38] B. Crosas, E. Cederlund, D. Torres, H. Jörnvall, J. Farrés, X. Parés, A vertebrate
aldo–keto reductase active with retinoids and ethanol, J. Biol. Chem. 276 (2001)
19132–19140.